August 5, 2024Open Access

Comparative effectiveness of extended‐release naltrexone and sublingual buprenorphine for treatment of opioid use disorder among Medicaid patients

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Extended-release naltrexone (XR-NTX) and sublingual buprenorphine (SL-BUP) are both approved for opioid use disorder (OUD) treatment in any medical setting. We aimed to compare the real-world effectiveness of XR-NTX and SL-BUP.

Leer artículo completoexternamente

Me gusta

Guardar

Ver artículo completo

Cite This Study

Ross et al. (Mon,) studied this question.

synapsesocial.com/papers/68e5d588b6db64358756bcbd https://doi.org/https://doi.org/10.1111/add.16630

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Defining indicators for drug overdose emergency department visits and hospitalisations in ICD-10-CM coded discharge data2021 · 56 citations
2The Hazards of Hazard Ratios2009 · 1,336 citations
3Injectable naltrexone, oral naltrexone, and buprenorphine utilization and discontinuation among individuals treated for opioid use disorder in a United States commercially insured population2017 · 334 citations
4Causal Knowledge as a Prerequisite for Confounding Evaluation: An Application to Birth Defects Epidemiology2002 · 1,473 citations
5Communicating health risks in science publications: time for everyone to take responsibility2018 · 11 citations

Me gusta

Guardar

Ver artículo completo